Lifestyle Drugs Market: By Disease (Erectile dysfunction, Balding, Weight loss, Cosmetic, Focus & Energy, Birth Control, Smoking Cessation) & By Region - Forecast(2018 - 2023)
Report Code : HCR 0290

Updated Date: 16 May, 2018  

1. Lifestyle Drugs Market – Market Overview
2. Executive Summary
3. Market Landscape
   3.1. Market Share Analysis
   3.2. Comparative Analysis
   3.3. Product Benchmarking
   3.4. End User Profiling
   3.5. Top 5 Financials Analysis
4. Lifestyle Drugs Market– Market Forces
   4.1. Drivers
      4.1.1. Growing population with lifestyle related health issues
      4.1.2. Increasing spending for fitness and health
   4.2. Restraints
   4.3. Opportunities
      4.3.1. Emerging economies
   4.4. Challenges
   4.5. Porter’s Five Forces Analysis
      4.5.1. Bargaining Power of Suppliers
      4.5.2. Bargaining Power of Buyers
      4.5.3. Threat of New Entrants
      4.5.4. Threat of Substitutes
      4.5.5. Degree of Competition
5. Lifestyle Drugs Market– Strategic Analysis
   5.1. Value Chain Analysis
   5.2. Pricing Analysis
   5.3. Opportunities Analysis
   5.4. Product/Market Life Cycle Analysis
   5.5. Suppliers and Distributors
6. Lifestyle Drugs Market, By Disease
   6.1. Erectile dysfunction
   6.2. Balding
   6.3. Weight loss
   6.4. Cosmetic
   6.5. Focus & Energy
   6.6. Birth Control
   6.7. Smoking Cessation
   6.8. Others
7. Lifestyle Drugs Market, By Geography
   7.1. Europe
      7.1.1. Germany
      7.1.2. France
      7.1.3. Italy
      7.1.4. Spain
      7.1.5. Russia
      7.1.6. U.K.
      7.1.7. Rest of Europe
   7.2. Asia Pacific
      7.2.1. China
      7.2.2. India
      7.2.3. Japan
      7.2.4. South Korea
      7.2.5. Rest of Asia-Pacific
   7.3. North America
      7.3.1. U.S.
      7.3.2. Canada
      7.3.3. Mexico
   7.4. Rest of the World (RoW)
      7.4.1. Brazil
      7.4.2. Rest of RoW
8. Lifestyle Drugs – Market Entropy
   8.1. Expansion
   8.2. Technological Developments
   8.3. Merger & Acquisitions, and Joint Ventures
   8.4. Supply- Contract
9. Company Profiles (Overview, Financials, SWOT Analysis, Developments, Product Portfolio)
   9.1. Pfizer Inc.
   9.2. Eli Lily
   9.3. Teva Pharmaceuticals
   9.4. Biocon Ltd.
   9.5. Mylan pharmaceuticals
   9.6. GlaxoSmithKline
   9.7. McNeil
   9.8. Johnson & Johnson
   9.9. Merck & Co. Inc.
   9.10. Dr. Reddy’s Laboratories
   9.11. Zydus Cadila
   9.12. Cipla
   9.13. Sun Pharmaceuticals
   9.14. Nicholas Piramal
   9.15. Alembic
   9.16. Proctor & Gamble
   9.17. Astrazeneca
   9.18. Novo Nordisk
   9.19. Amgen
   9.20. Lupin
*More than 40 Companies are profiled in this Research Report, Complete List available on Request*
"*Financials would be provided on a best efforts basis for private companies"
10. Appendix
   10.1. Abbreviations
   10.2. Sources
   10.3. Research Methodology
   10.4. Bibliography
   10.5. Compilation of Expert Insights
   10.6. Disclaimer